We have compared the effects of inhaled nitric oxide (iNO) and i.v. nitroglycerin (ivGTN) on the haemodynamic response to phenylephrineinduced hypertension (PEHT) in anaesthetized pigs. PEHT did not change either pulmonary vascular resistance or gas exchange throughout all experiments. Both treatments lowered pulmonary arterial pressure to the same extent (912.4% iNO; 913.7% ivGTN) and passively via an effect on left atrial pressure (926.3% iNO; 931.4% ivGTN). Both treatments failed to reverse the decrease in renal blood flow (RBFc) induced by PEHT, but both increased urinary flow (UF) (;128% iNO; ;148% ivGTN). IvGTN significantly increased plasma concentrations of nitrite and nitrate during (;22.7% arterial blood; ;26.2% venous blood) and beyond the period of infusion (iNO: ;6.4% and ;4.9%, respectively). In four control pigs (no PEHT), iNO markedly increased RBFc (;109%), glomerular filtration rate (;72.5%) and UF (;68.7%). We conclude that iNO may have direct cardiac and renal effects, probably via intervention of NO carrier forms such as S-nitroso compounds. (Br.
I.v. endothelium-independent nitrovasodilators such as sodium nitroprusside and nitroglycerin (ivGTN) produce their vasodilator effects by providing nitric oxide. 1 In contrast with i.v. medication, inhaled nitric oxide (iNO) is used commonly as a selective pulmonary vasodilator in experimental 2 and clinical 3 conditions. Inhaled NO is "microselective" in that it dilates only vessels directly adjacent to the alveolar units being ventilated. Therefore, in a hypoxaemic patient, iNO may improve oxygenation by improving ventilation/perfusion matching with redistribution of blood flow from unventilated shunted areas to ventilated but underperfused areas. 4 Some authors also explain the improved oxygenation with iNO by the fact that it produces local bronchodilation, 2 4 decreases vascular permeability and the appearance of pressure-driven pulmonary oedema, 4 and exerts a platelet antiaggregating effect. 2 A swine model has been used in the past to study the treatment of experimental pulmonary hypertension induced by hypoxia, 5 a thromboxane analogue, 6 oleic acid-induced ARDS 7 or sepsis. 2 4 Phenylephrine is a sympathomimetic amine commonly used in in vitro studies of the L-arginine:NO pathway 8 or to counteract clinical hypotension. 9 We have developed a phenylephrineinduced hypertension (PEHT) model in anaesthetized pigs. We wished to test the hypothesis that iNO does not affect the systemic circulation. Accordingly, we compared the effects of iNO and ivGTN on pulmonary and systemic haemodynamics and gas exchange, in addition to plasma and urinary concentrations of nitrite (NO 2 9 ) and nitrate (NO 3 CA, USA). Tidal volume was set at 15 After placing the electrocardiographic leads, we inserted an arterial pressure catheter (carotid artery), two venous infusion cannulae (external jugular vein, auricular vein), a pulmonary artery thermodilution catheter (for cardiac output), a core temperature probe and central venous catheter. Median sternotomy was performed, the pericardium opened and two catheters (12-gauge) inserted, one into the main pulmonary artery and the other into the left atrial appendage for pressure monitoring in addition to arterial and venous blood sampling for blood-gas analysis. The pericardium and chest wall were closed with sutures and metallic wires. Via a laparotomy, the left renal vein (renal venous blood sampling site) and both ureters were catheterized, and the left ovarian vein was ligated because of drainage into the renal vein. After instrumentation, 45 min were allowed to elapse to obtain a stable physiological state.
Each experiment was divided into four stages (I-IV) of 20 min (table 1) . Animals were enrolled in the experiments in random order.
Control arm. In control studies we evaluated the effect of time (experiment A), PEHT alone (experiment B) and iNO alone (experiment C).
Experimental arm. The four stages in the experiments were: (I) baseline measurements, (II) induction of PEHT by continuous infusion of phenylephrine diluted in saline (mean 14 Concentrations of gaseous NO and NO x s were monitored continuously using a chemiluminescence analyser (CLD700AL NO/NO x analyser, Ecophysics Tecan AG, Dürten, Switzerland). Based on our previous work, 5 6 we chose to study the effects of iNO 40 ppm. This dose was shown in several studies [3] [4] [5] [6] [7] to have a significant pulmonary vasodilator effect while ensuring an inspired fraction of NO 2 below 1 ppm with our system. 10 
RENAL MONITORING
Thirty minutes before the beginning of baseline measurements (stage I), a bolus of inulin 2 g and para-amino-hippuric acid (PAH) 2 g dissolved in 50 ml of glucose were administered, immediately followed by an infusion of inulin 2 g and PAH 4 g dissolved in 1000 ml of glucose at a constant rate of 1 ml min
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. Blood samples (4 ml) were obtained simultaneously from the left renal vein and carotid artery in order to measure packed cell volume (PCV), PAH and inulin concentrations, in addition to arterial and venous pNO x 9 concentrations. Blood samples were collected at the beginning of stage I and at the end of each 20-min period. Urine was collected separately in graduated cylinders from both ureters at 5-min interval during the whole procedure to measure urinary flow (UF), PAH and inulin concentrations, and uNO x
9
. The concentration of PAH in both urine and blood was measured using the technique described by Bratton and Marshall. 11 Renal plasma flow (RPF) was taken as PAH clearance (Cl PAH: C u (UF/C a ), where C u: PAH concentration in urine and C a :PAH concentration in arterial blood plasma). Renal plasma flow was corrected (RPFc) for PAH extraction coefficient . 13 After centrifugation at 1000 g for 15 min at room temperature, 100 l of supernatant were applied to a microreaction purge vessel chamber (270B NO analyser, Sievers Research Inc, Boulder, CO, USA) equipped with a temperature regulator and a condenser, which allowed direct introduction of prepared plasma and urine samples into the reducing solution. pNO X 9 and uNO X 9 concentrations were measured by conversion to NO using hot acidic vanadium (III) chloride. NO was eluted in a stream of nitrogen and detected by an ozone-induced chemiluminescence reaction. The NO/NO X analyser was connected directly to a data acquisition system (Mac Lab, Lamont Scientific Ltd., Downsview, Ont, Canada). Each sample was analysed in duplicate and measured once at the end of each 20-min period, as described previously. 13 CARDIORESPIRATORY VARIABLES Systolic (SAP), mean (MAP) and diastolic (DAP) systemic arterial pressures, mean pulmonary arterial pressure (PAP), left atrial pressure (LAP), central venous pressure (CVP), heart rate (HR) and cardiac output (CO; 5 ml of cold normal saline were injected in triplicate for each measurement) were recorded every 5 min in each period. Arterial and mixed venous blood-gas tensions were measured once at the end of each 20-min period.
DATA ANALYSIS
In the control arm, the sample size was n:4 for each experiment ( For each experiment, the effect of stage was evaluated with the one-factor repeated measures analysis of variance (F-ANOVA) and, when necessary, multiple comparisons were made using Fisher's protected least significant difference (LSD F ) test.
Between the five experiments, for the difference between two stages (e.g. stages-difference (III-I):between stages III and I), one-way analysis of variance (W-ANOVA) was used and multiple comparisons were made using Fisher's protected least significant difference (LSD W ) test. P:0.05 was considered significant, except for multiple comparisons where the global significance level of 0.05 was adjusted for the number of null hypotheses tested (P:0.008 for multiple comparisons within group LSD F and P:0.005 for multiple comparisons between the five groups LSD W ).
Results
For each experiment, the cardiovascular, renal and ). Comparison between experiments D and E on stages-differences (IV-III) and (IV-I) confirmed that pNO X 9 returned to baseline values in the iNO group but not in the ivGTN group.
Discussion
To our knowledge, this is the first report of PEHT in swine treated with nitrergic therapies and the first study of the haemodynamic extra-pulmonary effects of iNO.
The model used in these studies is well established. There was no mortality during the surgical preparations and we demonstrated with experiment A that cardiorespiratory variables remained stable during the period of the study and there were only minimal changes in renal function.
EXPERIMENT B

Cardiovascular effects
Phenylephrine acts on both ␣ 1 -and ␣ 2 -adrenoceptors 14 and induces hypertension (major ␣ 1 -effect) by constricting resistance and, to a lesser degree, capacitance vessels. 9 We observed no signs of tachyphylaxis with phenylephrine during the experiments. The observed passive post-capillary pulmonary hypertension with increased central filling pressures was secondary to the left ventricular haemodynamic effects of the acute increase in afterload induced by systemic hypertension. During the experiment, PVR did not change, in agreement with heterogenous 15 ␣-adrenergic innervation of large (5-7 mm in diameter) and small (2-3 mm in diameter) porcine pulmonary arteries and sparse or non-existant 16 ␣-adrenergic innervation of swine pulmonary resistance vessels.
Renal effects
The kidney reacted to phenylephrine-induced increase in SVR by a decrease in RBFc, 9 while GFR and UF remained unchanged. This suggests that phenylephrine constricted mainly the efferent arteriole and that GFR was maintained, despite a decrease in RBFc, by an increase in glomerular filtration fraction. 17 
Metabolic effects
The baseline values of pNO X 9 were higher than those measured in a porcine model of ARDS (30 mol litre
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). 7 However, the measurement techniques were different (chemiluminescence vs highpressure liquid chromatography based on the Griess reaction 7 ) and the surgical stress of our procedure may have stimulated release of endogenous NO. Furthermore, reported values for basal concentrations of pNO X 9 (mainly NO 3
9
) in humans vary greatly. [18] [19] [20] Our basal values for uNO X 9 were in accordance with those published previously in humans. 18 20 EXPERIMENT C Inhaled NO alone induced no cardiorespiratory modifications, but considerably altered renal function.
Transport of EDRF-NO
Several authors have suggested that EDRF-NO interacts with circulating molecules to regulate its activity, allowing its transport (NO carriers) 21 22 or promoting its degradation (NO scavengers). 23 Metal nitrosylation with haem and non-haem proteins and the NO reaction with nucleophil groups (e.g. sulfhydryl, amine) 24 of amino acids, peptides and proteins lead to the potential interaction and formation of many nitrosyl-haem adducts, S-non-protein-nitrosothiols (S-nitroso-L-cysteine), S-nitrosylated proteins (S-nitrosoalbumins, 21 Snitrosohaemoglobins 22 23 ), nitrosylated iron-sulphur clusters, dinitrosyl-iron complexes, 25 nitrosoamines and others.
Renal effects
Renal haemodynamics and diuresis were altered by iNO (experiment C), strongly supporting the presence of extra-pulmonary effects. It is now widely accepted that EDRF-NO is an important modulator of RBF and that regional microcirculation 26 may be mediated by endogenously produced EDRF-NO. Pharmacological block of EDRF-NO results in an increase in MAP and renal vascular resistance, and decrements in RBF, GFR, UF and sodium excretion. 27 There is some controversy regarding a selective effect of EDRF-NO block on either afferent or efferent arteriolar tone. 26 It would seem that EDRF-NO primarily alters afferent vascular tone, 28 thereby modifying the ability of the preglomerular vasculature to autoregulate glomerular capillary pressure. Several studies have emphasized an effect of EDRF-NO not only on glomerular but also on tubular function and the medullary circulation. 28 29 McKee, Scavone and Nathanson 30 showed that EDRF-NO, through generation of cGMP and stimulation of cGMP-dependent protein kinase(s), mediates the actions of several intercellular messengers to regulate renal tubular Na-K-ATPase. Inhibition of this sodium pump (e.g. by acetylcholine, bradykinin) would decrease transcellular water and sodium reabsorption from the tubular lumen, resulting in diuresis and natriuresis. Moreover, low doses of NO synthase inhibitors, that have no effect on either RBF or GFR, induce antidiuretic and antinatriuretic effects. 31 Here is the first report of exogenous iNO modulating renal function. Renal haemodynamic state may be influenced during iNO administration by circulating NO metabolites (e.g. NO X 9 ), 32 renal NO delivery through release from carrier S-nitroso compounds (e.g. Snitrosothiols) 33 after nitrosylation in the pulmonary circulation, or a local renal effect owing to an unknown paracrine influence stimulated by iNO. In vitro studies have shown that NaNO 2 did not influence renovascular tone in concentrations up to 0.1 mmol litre
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. 33 The diuretic effect of NaNO 3 was observed with a plasma NO 3 9 concentration of 38 mmol litre 91 in dogs. 32 In view of the rapid renal response to application and discontinuation of iNO, we postulate that iNO may be accompanied by nonselective, extra-pulmonary effects caused by local delivery of NO on peripheral territories that include the renal bed.
Metabolic effects
Nitric oxide reaching the circulation can be metabolized via three pathways: 23 (i) interaction with dissolved oxygen in blood to form NO 2 9 , (ii) reaction with oxyhaemoglobin to form methaemoglobin which in turn is reduced back to haemoglobin and NO 3 9 mainly by the NADPH-methaemoglobin reductase and peroxynitrite pathways, and (iii) combination with deoxyhaemoglobin to form the stable nitrosohaemoglobin (HbNO) or with carrier molecules to form S-nitrosothiols among others (see above). However, to date, the mechanisms by which NO is inactivated and eliminated are not fully known.
The concentration of pNO X 9 increased almost linearly throughout inhalation, and decreased on cessation of iNO. This result is in agreement with those of previous reports 19 20 which have shown a linear temporal increase in pNO X
9
. Approximately 40 mol of uNO X 9 were excreted in urine during the 40-min inhalation period, a result similar to that of Wennmalm and colleagues, 19 and the rate of elimination was maintained over the following 20 min. This implies that 23.6% of the retained NO was excreted in urine as uNO X 9 within 1 h after the start of inhalation. This early and fast elimination of iNO corroborates a previous study 20 that showed 69% of inhaled 15 NO was excreted in urine as 15 NO 3 9 within 24 h and another 4% from 24 to 48 h after the start of inhalation. Moreover, the decrease in pNO X 9 and maintenance of diuresis and high uNO X 9 concentrations after cessation of iNO suggest that NO X is stored in packaged forms before its release without vasoactive but with diuretic effects, transformation and elimination as NO X
.
EXPERIMENTAL ARM
Cardiovascular effects
Inhaled and i.v. nitrergic treatments partially reversed the passive pulmonary hypertension induced by phenylephrine. With the PEHT swine model, iNO 40 ppm was less effective in reducing PAP (50% reversal of the increase) than during hypoxia (108.7% at 40 ppm), 5 thromboxanemimetic infusion (61% at 40 ppm), 6 experimental ARDS (57.1% at 40 ppm) 7 or sepsis (84% at 10 ppm; 2 64.8% at 40 ppm 4 ). PVR remained unchanged throughout the experiment suggesting that the pulmonary resistance vasculature was not constricted and that both treatments did not act at this level in the PEHT swine model. Because the pulmonary vascular tone was unchanged by nitrergic treatments superimposed on PEHT, baseline gas exchange variables also remained unchanged.
The increase in PAP induced by phenylephrine was adjusted to comparable levels in both groups. Both treatments induced similar decreases in LAP, and consequently PAP and CVP. The decrease in LAP may be explained by a decrease in left atrial filling, increase in left compliance, decrease in left ventricular afterload or a combination of these effects. The first hypothesis is unlikely because CO did not change and there was no clinical sign of an increase in lung water as gas exchange variables remained constant. The second assumption implies, from the formed cGMP, 1 block of ␣ 1 effects on cardiac contraction and relaxation, 34 and a positive lusitropic effect increasing relaxation and diastolic distensibility of the heart. 35 A direct cardiac effect of endothelium-independent nitrovasodilators, such as depressed myocardial contractility, 36 improved ventricular relaxation and diastolic distensibility 37 is accepted. The decrease in systemic afterload (third postulate) was manifest with ivGTN infusion which induced a substantial decrease in SVR. An endogenous EDRF-NO signalling pathway has been found to regulate cardiac myocyte function. 38 The paracrine actions of EDRF-NO stimulated by substance P or bradykinin, particularly on left ventricular relaxation, are also well established. 39 The second and third hypotheses imply extrapulmonary effects with iNO. In a previous study, 5 we suggested that iNO had a direct cardiac effect. There was a slight modification of left ventricular afterload with iNO, as the observed decreases in SAP and MAP were statistically significant (LSD F : P:0.0001 and P:0.004, respectively) (table 2). We propose that iNO had a direct cardiac effect to explain the similar action of ivGTN and iNO on PAP, LAP and CVP. Our data indicate a larger decrease in SAP and MAP than that for DAP, suggesting that factors other than aortic compliance or SVR are modified by iNO. These other factors are usually related to changes in the mechanical performance of the heart as a pump. 40 A trend for iNO to decrease SVR or MAP was observed in several publications. 2 3 7 .
Renal effects
In experiments D and E, nitrergic treatments superimposed on phenylephrine infusion resulted in increases in UF without reversing the phenylephrine-induced decrease in RBFc. The primary phenylephrine site of action in the kidney seems to be the efferent arteriole in contrast with the afferent arteriole for EDRF-NO. This could explain the lack of reversibility for the decrease in RBFc induced by phenylephrine for both nitrergic treatments. Our findings also support a direct diuretic (and natriuretic?) effect of exogenous NO. Another hypothesis is the involvement of regulatory systems, either intrarenal such as the kallikrein-kinin system or prostaglandins (PGE 2 ), or extrarenal such as atrial natriuretic factor (ANF) or the oubain-like endogenous factor that increase diuresis. 41 However, EDRF-NO released from the endocardium or from the endothelial cells of the coronary vasculature, directly or through a decrease in LAP, or both, inhibits the release of ANF. 42 The results of experiment C and those from another study 33 give greater credence to intervention of exogenous NO in packaged forms.
Inhaled NO had a major effect on the kidney and a slight (on SAP and MAP) or no statistically apparent (on DAP and SVR) systemic effect. The kidney could be more sensitive to exogenous NO than the systemic circulation as demonstrated by the high sensitivity of RBF to NO synthase inhibition. 43 Indeed, the renovasculature showed significant modifications with low quantities of NO. Another hypothesis is that the kidney could more easily concentrate NO carriers or recuperate NO from its transport forms (local catabolism of S-nitroso compounds such as S-nitrosoglutathione, etc). The persistent diuresis after discontinuing PEHT and nitrergic treatments (stage IV) was in agreement with previous data. 32 33 It correlated with the persistent high pNO X 9 and uNO X 9 concentrations in experiment D or previous hypotheses such as intervention of other regulatory systems or a particular renal sensitivity to NO carriers for experiments C and E. It would imply that NO transported via GTN and that transported when NO is inhaled have similar (on the heart and kidney) and different (on the systemic circulation) effects. These could be explained by the nature of the implied packaged forms and their respective metabolism, particularly biotransformation of GTN to NO.
Metabolic effects
Because we deproteinized the plasma samples, NO (from iNO or released by GTN)-derived metabolites (NO 2 9 and NO 3 9 ) and GTN-derived metabolites (1,3-and 1,2-glyceryl dinitrate, and glyceryl mononitrate) were potentially measured as pNO X
9
. At the end of stage III, infusion of ivGTN significantly increased arterial and venous pNO X 9 concentrations (table 3) , and we observed only a statistical trend for iNO to increase pNO X 9 concentrations. This difference could be explained by a greater NO X intake for ivGTN than for iNO and the larger number of metabolites of GTN. Other studies found significant differences in pNO X 9 concentrations between baseline and iNO treatment 7 19 20 with a longer period of inhalation and larger sample size.
During stage IV, pNO X 9 concentrations remained high in experiment D (ivGTN), but decreased in experiment E (iNO), whereas uNO X 9 concentrations remained high in all experiments. NO might be released during stage IV from its carrier proteins with diuretic and without vasoactive effect, and metabolized in NO X
. Moreover, GTN-derived metabolites could be present at the end of stage IV and measured as NO X
. The absence of haemodynamic effects of these compounds during stage IV could be explained by their low potency or the nitrate tolerance phenomenon. The explanation for the pNO X 9 decrease in experiment E is disruption of iNO administration.
In summary, previous studies have shown clearly a marked effect of iNO on pulmonary hypertension in pulmonary vasoconstriction models. Furthermore, in the passive PEHT model without pulmonary vasoconstriction, iNO maintained its pulmonary antihypertensive property. These results suggest that iNO may have direct cardiac effects. This study also demonstrated a marked effect of iNO on renal function, similar to that of ivGTN. We conclude that iNO had extra-pulmonary effects in an in vivo swine model and consequently that iNO cannot be considered as a pure selective agent on the pulmonary vasculature.
